$GILD
3 articles on $GILD
- $MLYSBullish
KXCO's FDA Ontology Ranks Lorundrostat First After Its 10 November Update
KXCO's FDA ontology at kxco.ai/fda was updated in full on 10 November 2026. Its first screen now ranks Mineralys's lorundrostat (MLYS) first of the FDA decisions due within 90 days: decision 22 December, potential return +86%, per the page. Mineralys's shares fell 24.5% between reads on 20 October and 10 November. The update read six quarterly reports to 30 September by hand, and on KXCO's calculation Mineralys is funded to 12 October 2029, even if it repays its $100.0m loan by 30 June 2028.
Shayne Heffernan14 min - $NVDABullish
Week Ahead on Wall Street: CPI, Banks and Oil
September CPI lands on Wednesday after a Fed hike and a 10-year yield at its highest since 2002. JPMorgan, Goldman and Citi open bank earnings on Tuesday, ASML and TSMC report midweek, and Saudi pipeline attacks kept Brent at $104.72 on 9 October 2026, per CNBC. The KXCO AI Sector Ontology still shows contracted demand. This week ahead sets out the calendar, the three facts that would change the call, and why dips in the AI leaders remain buying opportunities.
Shayne Heffernan23 min - $BBIOBullish
The FDA Calendar to April 2027: 5 Biotech Stocks From the KXCO Biotech Ontology
The KXCO Biotech Ontology's board carries 11 pending FDA filings, due by 23 April 2027. Ranked on approval standing, the top five are BridgeBio's BBP-418, Cogent's bezuclastinib, Belite Bio's tinlarebant, Novo Nordisk's CagriSema and BioMarin's vosoritide. Ranked on consensus upside, they are Cullinan, Savara, Intellia, Mineralys and Pharvaris. No name is on both lists. This report covers BridgeBio, Cogent, Mineralys, Pharvaris and Savara.
Shayne Heffernan23 min